Finoriq research workspace
Actinium Pharmaceuticals, Inc. (ATNM) SEC Filings & Filing Highlights
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted. Review ATNM SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
- Company
- Actinium Pharmaceuticals, Inc. (ATNM)
- Ticker
- ATNM
- Market Cap
- $27.7M
- Latest Price
- $0.883
- Industry
- Biotech & Pharma
Actinium Pharmaceuticals, Inc. (ATNM) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Actinium Pharmaceuticals, Inc. (ATNM).
| Event | Form | Date |
|---|---|---|
| ACTINIUM PHARMACEUTICALS, INCIn accordance with the NYSE American LLC (“NYSE American”) requirements, on June 18, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) s... | 8-K8.01 | 2026-06-18 |
| Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-...Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing St... | 8-K7.01 | 2026-05-29 |
| Actinium Pharmaceuticals, Inc.: Exchange listing issueOn May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) i... | 8-K3.01 | 2026-05-29 |
| On February 11, 2026, Steve O’Loughlin tendered his resignation as the Chief Financial Officer...On February 11, 2026, Steve O’Loughlin tendered his resignation as the Chief Financial Officer of Actinium Pharmaceuticals, Inc. (the “Comp... | 8-K5.02 | 2026-02-13 |
| Broker Non-VotesA total of 15,494,573 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), were present in person or represen... | 8-K5.07 | 2025-11-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.